GastroClear™ is a non-invasive, blood-based molecular assay that analyses circulating microRNA (miRNA) biomarkers associated with gastric cancer risk. By detecting distinct molecular signatures linked to early-stage disease, GastroClear™ enables risk stratification before patients are referred for invasive procedures such as gastroscopy (OGDS).
Designed to function within a structured “Blood-First Triage” model, GastroClear™ supports clinicians in identifying individuals who may benefit from further diagnostic evaluation, while reducing unnecessary invasive investigations for low-risk patients. The test integrates seamlessly into hospital, screening centre, and primary care workflows and is supported by validated miRNA technology.
